Boehringer Ingelheim has signed a new collaboration and licence agreement with Bridge Biotherapeutics to develop autotaxin inhibitor BBT-877 to treat patients with fibrosing interstitial lung diseases.
The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
Under the deal, Bridge Biotherapeutics will secure upfront and near term payments of €45m (£40.5m).
Bridge will also secure over €1.1bn (£990m) based on the achievement of specific development, regulatory and commercial milestones, In addition, it is eligible to receive double-digit royalties.
Bridge Biotherapeutics CEO James Lee said: “Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide.”
LegoChem Biosciences had discovered BBT-877 candidate, which was licenced by Bridge Biotherapeutics in 2017 for further development.
At present, the BBT-877 is under phase I clinical studies and is expected to enter phase II testing within one year.
Initially, the partnership will develop the compound to treat IPF, which is a major focus area for Boehringer.